Epcoritamab for Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epcoritamab is a bispecific antibody. It works by simultaneously attaching to a molecule called CD20 on cancerous B-cells and a molecule called CD3 on effector T-cells, which are a type of immune cell. When epcoritamab binds to CD20 and CD3, it brings the two cells together and activates the T-cells to kill the cancerous B-cells. Epcoritamab may increase a patient's chances of achieving complete remission after CD19-directed CAR-T therapy, compared to standard observation.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, you cannot have received a CD20-targeted monoclonal antibody within 4 weeks prior to registration.
How is the drug Epcoritamab unique in treating lymphoma?
What data supports the effectiveness of the drug Epcoritamab for treating lymphoma?
Epcoritamab has shown promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with studies reporting overall response rates of 55.6% and complete response rates of 44.4%. It works by engaging T-cells to target and kill cancerous B-cells, and has been effective even in patients who did not respond to previous treatments.12345
Who Is on the Research Team?
Grzegorz S Nowakowski
Principal Investigator
Academic and Community Cancer Research United
Are You a Good Fit for This Trial?
This trial is for patients with B-cell lymphomas who haven't fully recovered after CD19-directed CAR-T therapy. Participants should have had a partial response or stable disease post-treatment, but not complete remission.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive epcoritamab subcutaneously on a specified schedule for up to 12 cycles, with MRI, PET/CT, and blood sample collection throughout the trial
Observation
Patients undergo observation per standard care, with MRI, PET/CT, and blood sample collection throughout the trial
Follow-up
Participants are monitored for safety and effectiveness after treatment, with follow-up every 90 days for 1 year and then every 180 days for up to 5 years
What Are the Treatments Tested in This Trial?
Interventions
- Epcoritamab
Epcoritamab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Academic and Community Cancer Research United
Lead Sponsor
National Cancer Institute (NCI)
Collaborator